Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
07:30am, Thursday, 25'th Feb 2021
–Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory
BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society's 2021 Annual Meeting
04:01pm, Wednesday, 24'th Feb 2021
Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET Company to Host Webcast to Discuss Proof-of-Concept Data fo
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
01:41pm, Monday, 22'nd Feb 2021
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Delta Air, Foot Locker, Nvidia, Petrobras and More Monday Afternoon Analyst Calls
12:46pm, Monday, 22'nd Feb 2021
With the trading day more than halfway over, the broad markets could not make up their mind on a direction.
BridgeBio Pharma's BBP-418 Muscular Dystrophy Study Moves Forward With Patient Dosing
01:01pm, Friday, 19'th Feb 2021
BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate ML Bio Solutions have dosed the first patient in the Phase 2 trial evaluating BBP-418 in patients with Limb-Girdle Muscular Dystrophy Type 2i (LGM
SAN FRANCISCO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines
BridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of Common Stock
08:00am, Friday, 12'th Feb 2021
PALO ALTO, Calif. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering
BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock
04:09pm, Thursday, 11'th Feb 2021
PALO ALTO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 05'th Feb 2021
PALO ALTO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1,
PALO ALTO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Venthera, which is focused on developing new treatment options for patients with rare vascular
BridgeBio's Eidos Merger And Its Rationale
12:09pm, Friday, 29'th Jan 2021
BridgeBio recently merged with Eidos, of which it previously owned 64%. AG10 is Eidos' lead asset.
BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes
11:04pm, Monday, 25'th Jan 2021
PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate princ
BridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million Convertible Senior Notes
07:00am, Monday, 25'th Jan 2021
PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced
BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger
04:30pm, Wednesday, 13'th Jan 2021
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today
